These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35338596)

  • 21. Coronary thrombosis. Effects of blood flow on the mechanism of thrombus formation.
    Goto S; Handa S
    Jpn Heart J; 1998 Sep; 39(5):579-96. PubMed ID: 9925990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Von Willebrand factor accelerates platelet adhesion and thrombus formation on a collagen surface in platelet-reduced blood under flow conditions.
    Tomokiyo K; Kamikubo Y; Hanada T; Araki T; Nakatomi Y; Ogata Y; Jung SM; Nakagaki T; Moroi M
    Blood; 2005 Feb; 105(3):1078-84. PubMed ID: 15459008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling Thrombus Shell: Linking Adhesion Receptor Properties and Macroscopic Dynamics.
    Kaneva VN; Dunster JL; Volpert V; Ataullahanov F; Panteleev MA; Nechipurenko DY
    Biophys J; 2021 Jan; 120(2):334-351. PubMed ID: 33472026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet thrombus formation on collagen type I. A model of deep vessel injury. Influence of blood rheology, von Willebrand factor, and blood coagulation.
    Badimon L; Badimon JJ; Turitto VT; Vallabhajosula S; Fuster V
    Circulation; 1988 Dec; 78(6):1431-42. PubMed ID: 3263902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shorter PFA-100 closure times in neonates than in adults: role of red cells, white cells, platelets and von Willebrand factor.
    Roschitz B; Sudi K; Köstenberger M; Muntean W
    Acta Paediatr; 2001 Jun; 90(6):664-70. PubMed ID: 11440101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.
    Chauhan AK; Kisucka J; Lamb CB; Bergmeier W; Wagner DD
    Blood; 2007 Mar; 109(6):2424-9. PubMed ID: 17119108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100?
    Watala C; Golanski J; Rozalski M; Boncler MA; Luzak B; Baraniak J; Korczynski D; Drygas W
    Thromb Res; 2003 Mar; 109(5-6):299-306. PubMed ID: 12818254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets.
    Alevriadou BR; Moake JL; Turner NA; Ruggeri ZM; Folie BJ; Phillips MD; Schreiber AB; Hrinda ME; McIntire LV
    Blood; 1993 Mar; 81(5):1263-76. PubMed ID: 8443388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer.
    Zhu S; Gilbert JC; Hatala P; Harvey W; Liang Z; Gao S; Kang D; Jilma B
    J Thromb Haemost; 2020 May; 18(5):1113-1123. PubMed ID: 32011054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.
    Slobodianuk TL; Kochelek C; Foeckler J; Kalloway S; Weiler H; Flood VH
    J Thromb Haemost; 2019 Jan; 17(1):63-71. PubMed ID: 30565388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
    Favaloro EJ; Thom J; Patterson D; Just S; Baccala M; Dixon T; Meiring M; Koutts J; Rowell J; Baker R
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):475-83. PubMed ID: 19584715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of von Willebrand factor in thrombus formation.
    Ruggeri ZM
    Thromb Res; 2007; 120 Suppl 1(Suppl 1):S5-9. PubMed ID: 17493665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet GpIba binding to von Willebrand Factor under fluid shear:contributions of the D′D3-domain, A1-domain flanking peptide and O-linked glycans.
    Madabhushi SR; Zhang C; Kelkar A; Dayananda KM; Neelamegham S
    J Am Heart Assoc; 2014 Oct; 3(5):e001420. PubMed ID: 25341886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of the von Willebrand factor with platelets and thrombosis.
    Perutelli P; Mori PG
    Recenti Prog Med; 1997 Nov; 88(11):526-9. PubMed ID: 9401429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Clopidogrel on Thrombus Formation in an Ex Vivo Parallel Plate Flow Chamber Model Cannot Be Reversed by Addition of Platelet Concentrates or vWF Concentrate.
    Jahn K; Suchodolski K; Schäfer A; Sahlmann B; Küster U; Echtermeyer F; Calmer S; Theilmeier G; Johanning K
    Anesth Analg; 2017 Apr; 124(4):1091-1098. PubMed ID: 28244953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.
    Cattaneo M; Federici AB; Lecchi A; Agati B; Lombardi R; Stabile F; Bucciarelli P
    Thromb Haemost; 1999 Jul; 82(1):35-9. PubMed ID: 10456451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice.
    Verhenne S; Denorme F; Libbrecht S; Vandenbulcke A; Pareyn I; Deckmyn H; Lambrecht A; Nieswandt B; Kleinschnitz C; Vanhoorelbeke K; De Meyer SF
    Blood; 2015 Oct; 126(14):1715-22. PubMed ID: 26209660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time.
    Wadanoli M; Sako D; Shaw GD; Schaub RG; Wang Q; Tchernychev B; Xu J; Porter TJ; Huang Q
    Thromb Haemost; 2007 Aug; 98(2):397-405. PubMed ID: 17721623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.